Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Prem Harichander Thurairajah"'
Autor:
Yu Jun Wong, Prem Harichander Thurairajah, Rahul Kumar, Kwong Ming Fock, Ngai Moh Law, Sin-Yoong Chong, Fria Gloriba Manejero, Tiing-Leong Ang, Eng Kiong Teo, Jessica Tan
Publikováno v:
Clinical and Molecular Hepatology, Vol 27, Iss 3, Pp 474-485 (2021)
Background/Aims Despite the disproportionally high prevalence rates of hepatitis C virus (HCV) amongst the incarcerated population, eradication remains challenging due to logistic and financial barriers. Although treatment prioritization based on dis
Externí odkaz:
https://doaj.org/article/595e097cf4044c6e88fd020c101e4fdd
Publikováno v:
Clinical and Molecular Hepatology, Vol 25, Iss 3, Pp 326-330 (2019)
Externí odkaz:
https://doaj.org/article/946e7a9b374f4af299df57d1896238c6
Autor:
Yu Jun Wong, Si Yuan Chew, John Chen Hsiang, Prem Harichander Thurairajah, Rahul Kumar, Eng Kiong Teo, Roshni Sadashiv Gokhale, Imran Bin Mohamed Noor, Jessica Tan
Publikováno v:
Clinical and Molecular Hepatology, Vol 25, Iss 2, Pp 218-222 (2019)
Externí odkaz:
https://doaj.org/article/840109084e7944b2a30047df5367dcdc
Autor:
Jing Hong, Loo, Wen Xin Flora, Xu, Jun Teck, Low, Wei Xuan, Tay, Le Shaun, Ang, Yew Chong, Tam, Prem Harichander, Thurairajah, Rahul, Kumar, Yu Jun, Wong
Publikováno v:
World Journal of Hepatology. 14:1248-1257
Hepatitis C virus (HCV) is a leading cause of liver cirrhosis and hepatocellular carcinoma globally. Sofosbuvir/velpatasvir (SOF/VEL) is an effective pan-genotypic direct-acting antiviral combination for treatment of chronic HCV infection. While the
Autor:
Sin-Yoong Chong, Prem Harichander Thurairajah, Tiing Leong Ang, Yu Jun Wong, Eng Kiong Teo, Fria Gloriba Manejero, Ngai Moh Law, Jessica Tan, Kwong Ming Fock, Rajesh Kumar
Publikováno v:
Clinical and Molecular Hepatology, Vol 27, Iss 3, Pp 474-485 (2021)
Clinical and Molecular Hepatology
Clinical and Molecular Hepatology
Background/Aims: Despite the disproportionally high prevalence rates of hepatitis C virus (HCV) amongst the incarcerated population, eradication remains challenging due to logistic and financial barriers. Although treatment prioritization based on di
Autor:
Weiquan Li, Andrew Kwek, Prem Harichander Thurairajah, Tiing Leong Ang, Yu Bin Tan, Loshini Senthil Kumar, Ngai Moh Law, Zheng Cong Lee, Eng Kiong Teo, Kwong Ming Fock, Rajesh Kumar, Jingyun Koh, Jessica Tan, Yu Jun Wong
Publikováno v:
Journal of Gastroenterology and Hepatology. 36:1300-1308
BACKGROUND AND AIM Real-world data on sofosbuvir/velpatasvir with and without ribavirin (SOF/VEL ± RBV), particularly among patients with genotype 3 (GT3) decompensated cirrhosis, prior treatment, coinfection, and hepatocellular carcinoma (HCC), are
Publikováno v:
Journal of Gastroenterology and Hepatology. 36:1110-1117
Author(s): Chaillon, Antoine; Thurairajah, Prem Harichander; Hsiang, John Chen; Martin, Natasha K | Abstract: Background and aimThe vast majority of hepatitis C virus (HCV) infection in Singapore is among those with a history of injecting drug use (I
Publikováno v:
Clinical and Molecular Hepatology
Clinical and Molecular Hepatology, Vol 25, Iss 3, Pp 326-330 (2019)
Clinical and Molecular Hepatology, Vol 25, Iss 3, Pp 326-330 (2019)
Autor:
Yu Jun Wong, Prem Harichander Thurairajah, Rajneesh Kumar, Grace Lai-Hung Wong, Vicky Wing-Ki Hui, Chen-Hua Liu, Jia-Horng Kao
Publikováno v:
Clinical Hepatology.
Background Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) was approved as salvage therapy for NS5A-experienced hepatitis C virus (HCV) infected patients. However, the real-world data of SOF/VEL/VOX remained limited in Asia. We aim to analyse the r
Autor:
Jing Hong Loo, Flora Xu, Gerald Low, Wei Xuan Tay, Le Shaun Ang, Steve Yew-chong Tam, Prem Harichander Thurairajah, Rahul Kumar, Yu Jun Wong
Publikováno v:
Journal of Hepatology. 77:S567